Immix Biopharma, Inc.
NASDAQ:IMMX
2.09 (USD) • At close May 9, 2025
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2024 Q4 | 2024 Q3 | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 Q3 | 2023 Q2 | 2023 Q1 | 2022 Q4 | 2022 Q3 | 2022 Q2 | 2022 Q1 | 2021 Q4 | 2021 Q3 | 2021 Q2 | 2021 Q1 | 2020 Q4 | 2020 Q3 | 2020 Q2 | 2020 Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 0 | 0 | 0 | 0 | 0.005 | 0 | 0 | 0 | -89.517 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue
| 0 | 0 | 0.024 | 0.024 | 0.003 | 0.001 | 0.001 | 0.001 | 0.001 | 0.001 | 0 | 0.001 | 0.001 | 0.001 | 0 | 0.001 | 0 | 0.001 | 0 | 0 |
| Gross Profit
| 0 | 0 | -0.024 | -0.024 | 0.002 | -0.001 | -0.001 | -0.001 | -89.518 | -0.001 | -0 | -0.001 | -0.001 | -0.001 | 0 | -0.001 | 0 | -0.001 | 0 | 0 |
| Gross Profit Ratio
| 0 | 0 | 0 | 0 | 0.357 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Reseach & Development Expenses
| 1.374 | 4.446 | 2.224 | 3.249 | 3.101 | 2.106 | 2.209 | 1.319 | 2.263 | 0.696 | 0.608 | 0.63 | 0.009 | 0.03 | 0.063 | 0.025 | 0.083 | 0.045 | 0.06 | 0.06 |
| General & Administrative Expenses
| 3.613 | 2.949 | 2.478 | 2.341 | 2.275 | 2.418 | 1.511 | 1.202 | 1.532 | 0.837 | 0.953 | 0.701 | 0.589 | 0.318 | 0.18 | 0.138 | 0.07 | 0.046 | 0.045 | 0.045 |
| Selling & Marketing Expenses
| 0 | 0 | 0 | 0.014 | -0.01 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| SG&A
| 3.613 | 2.949 | 2.478 | 2.356 | 2.265 | 2.418 | 1.511 | 1.202 | 1.532 | 0.837 | 0.953 | 0.701 | 0.589 | 0.318 | 0.18 | 0.138 | 0.07 | 0.046 | 0.045 | 0.045 |
| Other Expenses
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -0 | 0 | 0 | 0 |
| Operating Expenses
| 4.987 | 7.395 | 4.702 | 5.604 | 5.365 | 4.524 | 3.721 | 2.521 | 3.795 | 1.533 | 1.561 | 1.33 | 0.598 | 0.348 | 0.243 | 0.163 | 0.154 | 0.091 | 0.104 | 0.104 |
| Operating Income
| -4.987 | -7.395 | -4.702 | -5.628 | -5.368 | -4.524 | -3.721 | -2.521 | -3.795 | -1.533 | -1.561 | -1.33 | -0.598 | -0.348 | -0.243 | -0.163 | -0.154 | -0.091 | -0.105 | -0.105 |
| Operating Income Ratio
| 0 | 0 | 0 | 0 | -1,122.176 | 0 | 0 | 0 | 0.042 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Other Income Expenses Net
| 0.186 | 0.257 | 0.307 | 0.268 | 0.229 | 0.187 | 0.129 | 0.028 | 0 | 0 | -0 | -0 | -22.156 | -0.054 | 0.036 | -0.853 | -0.6 | -0.023 | -0.027 | -0.027 |
| Income Before Tax
| -4.801 | -7.138 | -4.396 | -5.322 | -5.147 | -4.337 | -3.592 | -2.493 | -3.795 | -1.533 | -1.561 | -1.33 | -22.754 | -0.402 | -0.207 | -1.015 | -0.753 | -0.115 | -0.131 | -0.131 |
| Income Before Tax Ratio
| 0 | 0 | 0 | 0 | -1,075.936 | 0 | 0 | 0 | 0.042 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Income Tax Expense
| 0.011 | 0.011 | 0.01 | 0.009 | 0.008 | 0.007 | 0.006 | 0.005 | 0.005 | 0.002 | 0.002 | 0.002 | 0.001 | 0.001 | 0.002 | 0.002 | 0.012 | 0.002 | 0.002 | 0.002 |
| Net Income
| -4.812 | -7.149 | -4.393 | -5.259 | -5.09 | -4.281 | -3.576 | -2.498 | -3.8 | -1.535 | -1.563 | -1.332 | -22.755 | -0.403 | -0.209 | -1.017 | -0.766 | -0.116 | -0.133 | -0.133 |
| Net Income Ratio
| 0 | 0 | 0 | 0 | -1,063.86 | 0 | 0 | 0 | 0.042 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS
| -0.17 | -0.24 | -0.15 | -0.22 | -0.26 | -0.23 | -0.24 | -0.18 | -0.29 | -0.11 | -0.11 | -0.096 | -3 | -0.056 | -0.024 | -0.12 | -0.1 | -0.015 | -0.039 | -0.039 |
| EPS Diluted
| -0.17 | -0.24 | -0.15 | -0.22 | -0.26 | -0.23 | -0.24 | -0.18 | -0.29 | -0.11 | -0.11 | -0.096 | -3 | -0.056 | -0.024 | -0.12 | -0.1 | -0.015 | -0.039 | -0.039 |
| EBITDA
| -4.946 | -7.369 | -4.678 | -5.587 | -5.144 | -4.336 | -3.72 | -2.52 | -3.794 | -1.533 | -1.561 | -1.329 | -22.709 | -0.347 | -0.153 | -0.987 | -0.728 | -0.091 | -0.104 | -0.104 |
| EBITDA Ratio
| 0 | 0 | 0 | 0 | -1,075.292 | 0 | 0 | 0 | 0.042 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |